5-hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle?
5-Hydroxytryptamine, a recent addition to the list of hormonal triggers for atrial fibrillation (AF), may play a pivotal role in the induction of AF related not only to cardiac surgery but also to acute coronary syndromes, valvular heart disease, cardiomyopathies, alcoholism, aging, and conducting tissue disease. This review examines the supporting laboratory and clinical evidence and provides a comprehensive insight into the basic underlying mechanisms involved. It also delves into the potential benefits and limitations of 5-HT4 antagonists in the prevention and management of this arrhythmia.
Yusuf
Shamil
S
Department of Cardiovascular Medicine, St. Georges Hospital Medical School, London, United Kingdom. syusuf@sghms.ac.uk
Al-Saady
Naab
N
Camm
A John
AJ
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000378:metabolism / Q000503:physiopathology*; D006321:Heart / Q000503:physiopathology; D006325:Heart Atria / Q000378:metabolism / Q000503:physiopathology*; D006329:Heart Conduction System / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D009200:Myocardial Contraction; D009206:Myocardium / Q000378:metabolism; D011985:Receptors, Serotonin / Q000145:classification* / Q000378:metabolism*; D012701:Serotonin / Q000145:classification* / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin